ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
0.00%
US Dollar vs MXN
16.93169
-0.31%
Brent Oil
83.675
0.66%
Bitcoin
64,184.93
0.29%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Noticias

MRK

Merck (MRK)

Merck and Co Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:MRK
FechaHoraFuenteTítuloSímboloCompañía
01/05/202406:15Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
29/04/202408:00Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
25/04/202415:40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202408:09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202406:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
25/04/202405:30Business WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
19/04/202406:04PR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
19/04/202406:04PR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
10/04/202406:13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:MRKMerck and Co Inc
04/04/202405:45Business WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
03/04/202407:00Business WireREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerNYSE:MRKMerck and Co Inc
01/04/202405:45Business WireMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25NYSE:MRKMerck and Co Inc
28/03/202405:45Business WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsNYSE:MRKMerck and Co Inc
27/03/202405:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:MRKMerck and Co Inc
26/03/202417:21Business WireFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)NYSE:MRKMerck and Co Inc
21/03/202405:45Business WireMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
19/03/202408:00Business WireMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsNYSE:MRKMerck and Co Inc
15/03/202415:23PR Newswire (US)FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformNYSE:MRKMerck and Co Inc
15/03/202405:45Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
13/03/202402:00Business WireMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9NYSE:MRKMerck and Co Inc
11/03/202407:15Business WireMerck Completes Acquisition of Harpoon Therapeutics, Inc.NYSE:MRKMerck and Co Inc
06/03/202409:25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NYSE:MRKMerck and Co Inc
05/03/202408:03IH Market NewsFutures Pointing To Continued Weakness On Wall StreetNYSE:MRKMerck and Co Inc
05/03/202405:45Business WireMerck to Participate in the Barclays 26th Annual Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
04/03/202405:45Business WireMerck to Participate in the Leerink Partners Global Biopharma Conference 2024NYSE:MRKMerck and Co Inc
27/02/202405:45Business WireMerck to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:MRKMerck and Co Inc
23/02/202405:20Business WireMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of RecurrenceNYSE:MRKMerck and Co Inc
20/02/202415:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
20/02/202405:45Business WireFDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial CarcinomaNYSE:MRKMerck and Co Inc
15/02/202415:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Su Consulta Reciente

NYSE
VZ
Verizon Communications
FX
EURMXN
Euro vs MXN
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
GOOGL
Alphabet
COIN
SOLUSD
Solana
CCOM
US500
US 500
NYSE
MRK
Merck
USOTC
DTEGY
Deutsche Telekom (QX)
PM
XAUUSD
Gold vs US Dollar
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados